Post-earnings recap
Reported
Thu, Mar 5, 2020
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Aurinia Pharmaceuticals reported a loss per share of $0.78, but the stock rose by 1.57% following the earnings announcement. The increase in stock price may reflect investor optimism despite the lack of revenue data and guidance. Investors will need to wait for further information from management to understand the company's future direction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.78 | N/A | — |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based solely on numerical results.